Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbingdon Healt. Regulatory News (ABDX)

Share Price Information for Abingdon Healt. (ABDX)

Share Price is delayed by 15 minutes
Get Live Data
10.25    0.00 (0.00%)
Bid:
10.00
Ask:
10.50
Spread: 0.50 (5.00%)
Market Cap: £25.74m
ABDX Live PriceLast checked at - London Stock Exchange

Intraday Abingdon Healt. Share Chart

Open Offer Launch, Posting of Circular, GM Notice

2 Dec 2021 17:43

RNS Number : 4427U
Abingdon Health PLC
02 December 2021
 

2 December 2021

 

 

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

 

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

Launch of Open Offer, Posting of Circular, Notice of General Meeting

 

York, U.K. 2 December 2021: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, is pleased to announce that further to the Company's announcement on 1 December 2021 (the "Proposed Fundraising"), the Company will today post a Circular to Qualifying Shareholders regarding the Open Offer of up to 4,000,000 Open Offer Shares in the Company at the Issue Price of 25 pence per Open Offer Share to raise up to approximately £1 million (before expenses).

 

Pursuant to the Open Offer, Qualifying Shareholders will be given the opportunity to subscribe for:

 

1 Open Offer Share for every 23.9247785 Existing Ordinary Shares

held by each Qualifying Shareholder on the Record Date.

Any Open Offer Shares not subscribed for by Qualifying Shareholders will be available to Qualifying Shareholders under the Excess Application Facility and as such, Qualifying Shareholders seeking to limit their dilution from the Placing, the Subscription and the Primary Bid Offer can also request additional Open Offer Shares ("Excess Shares") under the Excess Application Facility. The Open Offer is not being underwritten.

 

The Open Offer is conditional upon, among other matters, the Second Placing becoming or being declared unconditional in all respects and not being terminated before Second Admission.

 

Posting of Circular

 

Further details regarding the Open Offer are available in the Circular, which has been posted today to Qualifying Shareholders, along with the Application Form (where applicable). The Circular will also be made available on the Company's website: www.abingdonhealth.com/investors/

 

Notice of General Meeting

A notice convening a General Meeting of the Company is set out at the end of the Circular. The General Meeting has been convened for 10.30 a.m. on 20 December 2021 at the offices of Abingdon Health plc at York Biotech Campus, Sand Hutton, York, YO41 1LZ.

 

Capitalised terms used in this announcement have the meanings given to them in the Circular, unless the context provides otherwise.

 

Enquiries:

 

Abingdon Health plc

www.abingdonhealth.com/investors/

Chris Yates, Chief Executive Officer

Via Walbrook PR

Melanie Ross, Chief Financial Officer

Christopher Hand, Non-Executive Chairman

Singer Capital Markets Securities Limited (Sole Bookrunner and Broker)Singer Capital Markets Advisory LLP (Nominated Adviser)

Tel: +44 (0)20 7496 3000

Shaun Dobson, Peter Steel, Alex Bond (Corporate Finance)

Tom Salvesen (Corporate Broking)

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com

Paul McManus / Phillip Marriage

Mob: +44 (0)7980 541 893 / +44 (0)77867 984 082

Alice Woodings

Mob: +44 (0)7407 804 654

 

 

 

Expected timetable of principal events:

 

2021

Record Date for entitlement under the Open Offer

30 November

Announcement of the Fundraising

7.00 a.m. on 1 December

Announcement of the results of the Placing, the Subscription and the PrimaryBid Offer

1 December

Publication and posting of the Circular, Notice of General Meeting, Form of Proxy and, to Qualifying Non-Crest Shareholders, the Application Form

2 December

Ex-Entitlement Date of the Open Offer

2 December

Open Offer Entitlements and Excess Open Offer Entitlements credited to stock accounts in CREST of Qualifying CREST Shareholders

3 December

Admission of the First Placing Shares to trading on AIM and commencement of dealings

8 a.m. on 3 December

Where applicable, expected date for CREST accounts to be credited in respect of First Placing Shares in uncertificated form

3 December

Latest recommended time and date for requested withdrawal of Open Offer Entitlements

4.30 p.m. on 13 December

Latest time and date for depositing Open Offer Entitlements in CREST

3.00 p.m. on 14 December

Latest time and date for splitting of Application Forms under the Open Offer

3.00 p.m. on 15 December

Latest time and date for receipt of Forms of Proxy and CREST voting instructions

10.30 a.m. on 16 December

Latest time and date for receipt of Application Forms and payment in full under the Open Offer and settlement of relevant CREST instructions (as appropriate)

11.00 a.m. on 17 December

Where applicable, expected date for dispatch of definitive share certificates for First Placing Shares in certificated form

17 December

General Meeting

10.30 a.m. on 20 December

Results of the General Meeting and the Open Offer announced

20 December

Admission of the Second Admission Shares to trading on AIM and commencement of dealings

8 a.m. on 21 December

Where applicable, expected date for CREST accounts to be credited in respect of Second Admission Shares in uncertificated form

21 December

Where applicable, expected date for dispatch of definitive share certificates for Second Admission Shares in certificated form

6 January 2022

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPGGCPUPGGMP
Date   Source Headline
29th May 20267:00 amRNS-RPresentation at Mello2026
27th May 20267:00 amRNSUS tax credit agreement
19th May 20267:00 amRNSEarn-out Consideration and Issue of Equity
11th May 20267:00 amRNS-RLaunch of LVOne Stroke Test by UpFront Diagnostics
7th May 20265:38 pmRNSHolding(s) in Company
6th May 20267:00 amRNS-RUpdate on Partnership with 4TEEN4 Pharmaceuticals
21st Apr 20267:00 amRNSAdmission to trading on OTCQB in the US
15th Apr 20267:00 amRNSEMI Share Option Scheme
14th Apr 20267:00 amRNSTrading to commence on the OTCQB in the US
30th Mar 20267:00 amRNS£4.8m contracts awarded
17th Mar 20267:00 amRNSHalf-year Financial Report
17th Mar 20267:00 amRNSHalf-year Financial Report
12th Mar 20267:00 amRNS$2.5m Contract for clinical self-test development
10th Mar 20267:00 amRNSTrading on the OTCQB Venture Market in the US
5th Mar 20267:00 amRNSNotice of Results
15th Jan 20267:01 amRNSTrading Update
15th Jan 20267:00 amRNSAppointment of NOMAD & Corporate Broker
29th Dec 20252:35 pmRNSExercise of options and total voting rights
29th Dec 20252:35 pmRNSExercise of options and total voting rights
18th Dec 20257:00 amRNS-REuropean patent for AppDx® smartphone reader
10th Dec 20251:47 pmRNSResult of Annual General Meeting
4th Dec 20257:00 amRNSVesting and Award of Options under LTIP
2nd Dec 20253:08 pmRNSHolding(s) in Company
14th Nov 20252:00 pmRNSNotice of AGM & Publication of 2025 Annual Report
11th Nov 20257:00 amRNSFinal Results
10th Nov 20257:00 amRNSc.US$2m multiplex diagnostic test contract win
6th Nov 20257:00 amRNSLaunch of seaweed-based lateral flow housings
4th Nov 20254:58 pmRNSHolding(s) in Company
4th Nov 20257:00 amRNSHolding(s) in Company
3rd Nov 20257:00 amRNSNotice of Results
30th Oct 20259:43 amRNSResult of Meeting and TVR
17th Oct 20257:00 amRNSResult of Retail Offer
14th Oct 20257:58 amRNSLaunch of Retail Offer
14th Oct 20257:47 amRNSResult of Placing and Notice of GM
13th Oct 20255:04 pmRNSProposed Placing and Retail Offer
1st Sep 20257:00 amRNSUS CDMO Operations Update
14th Aug 20256:01 pmRNSDirector/PDMR Shareholding
5th Aug 20257:00 amRNSTrading update
31st Jul 20257:00 amRNSc. US$2.5m companion diagnostic test contract win
12th Jun 20257:00 amRNS€2m contract win for companion diagnostic test
4th Jun 20257:00 amRNS-RUpdate re. strategic partnership with FOFH
2nd Jun 20257:00 amRNS-RAvian flu (H5N1) lateral flow test
2nd May 202512:00 pmRNSAward of Options under LTIP
24th Mar 20257:00 amRNSDirectorate Changes
24th Mar 20257:00 amRNSHalf-year Report
17th Mar 20257:00 amRNSNotice of Results
17th Mar 20257:00 amRNSSalistick™ to be launched in Germany
27th Jan 20257:00 amRNSFunding award to develop test for malaria parasite
19th Dec 20247:00 amRNSDirectorate Change
17th Dec 20247:09 amRNSAbingdon Analytical Laboratory opens at Doncaster

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.